GSK's Walmsley Focused On Upcoming Launches Amid 'Uncertain' Times
New CEO confirmed GSK's commitment to maintaining its three business unit structure ‒ "as long as all three businesses continue to perform competitively" ‒ as she chaired her first quarterly results presentation at the helm of the big pharma.
You may also be interested in...
US FDA OK for its two-shot shingles regime gives GSK a likely blockbuster with a clear best-in-class profile.
Teva's decision to launch an authorized generic version of AirDuo, a drug made up of the same active ingredients in GSK's Advair, at a steep discount to typical brand drugs for asthma will help encourage use, even though it is not interchangeable.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.